plus the purine nucleoside analog fludarabine was more effective than fludarabine alone.
Letters to the Editor In the nucleus, b-catenin serves as a transcriptional co-activator by displacing repressive elements on TCF/LEF factors such as TCF7L2 (aka TCF4), and stimulating Wnt target gene transcription. 2 There is conflicting evidence in the literature concerning the role of canonical Wnt signaling in hematopoiesis. Some studies suggest the pathway is important for normal hematopoietic stem cell (HSC) self-renewal and development, whereas others demonstrate how constitutive activation impairs differentiation and exhausts the HSC pool (reviewed by Staal and Luis 1 ). In the context of hematological malignancy, the aberrant expression/activity of b-catenin has frequently been reported in leukemia, and may contribute to the establishment and maintenance of leukemiainitiating cells (reviewed by Fung et al. 3 ). More recently, we have shown that dysregulation of a closely related Wnt signaling component, g-catenin (aka plakoglobin), is also frequently overexpressed in acute myeloid leukemia 4 and implicated in leukemogenesis. 5 The role of g-catenin and Wnt signaling in hematopoietic reconstitution is controversial, 1 however, there have been no studies investigating whether g-catenin influences hematopoietic differentiation. We, therefore, sought to characterize g-catenin's expression level, subcellular localization and importance to normal human hematopoiesis.
To determine g-catenin expression levels throughout hematopoiesis, we optimized a flow cytometric assay to determine the expression of this protein in human cord blood (CB) and bone marrow (BM) subpopulations, defined by cell surface marker expression (see Supplementary Methods and Supplementary Figures S1-S3 for subpopulation analysis strategy). Figure 1a shows that g-catenin expression was strongly expressed in both HSC (CD34 þ CD38 À ) and hematopoietic progenitor cells (CD34 , suggesting a previously undefined role in myeloid differentiation. Conversely, g-catenin expression, decreased in both CD3
þ T cells and CD19 þ B cells from the level observed in hematopoietic stem/progenitor cells (HSPC), consistent with a report indicating functional redundancy of this protein in murine lymphopoiesis. 6 Finally, differentiated erythrocytes (GlyA þ TO-PRO-3) exhibited no detectable g-catenin expression (data not shown) in agreement with proteomic analyses of human erythrocytes. 7 The expression profile of g-catenin was similar between subpopulations of human CB and BM (Figure 1b) .
Within the epithelial context, g-catenin has been characterized as a dual-function molecule with roles in both adhesion and transcription. 8 As these roles are associated with distinct subcellular locations, we examined the intracellular localization of g-catenin using a validated confocal laser scanning microscopy analysis (Supplementary Figure S4) in subpopulations exhibiting the highest expression levels (HSPC, granulocytes, monocytes). Purified CB-derived CD34 þ cells demonstrated a predominantly cytoplasmic localization of g-catenin protein; little protein could be detected within the nucleus of these cells and there was also no clear-membrane-associated g-catenin as seen in epithelial cells 9 ( Figures 1c and f , and further color images are available in Supplementary Figure S5 ). This cytosolic pool of g-catenin may serve a structural role or represent a reserve of protein available for nuclear translocation; however, in a previous study, we were unable to force the nuclear translocation of g-catenin in these cells using Wnt agonists or ectopic expression. 4 These data showed that expression level of cytoplasmic g-catenin alone does not strongly influence its nuclear localization, indicating the need for additional cues to promote g-catenin translocation in normal haematopoietic cells. To study maturing populations within buffy coat fractions, we surface-stained cells to identify lineage. In CD15
Hi granulocytes, g-catenin remained predominantly localized to the cytosol, however, signal was detectable in the nuclear region of these cells particularly those exhibiting metamyelocyte/segmented morphology (Figures 1d and f , and further color images are available in Supplementary Figure S6) . Interestingly, normal human granulopoiesis is known to be dependent on the expression of the LEF-1 transcription factor, 10 an established downstream binding partner of catenins, which can direct their nuclear localization.
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CD14
þ monocytes demonstrated considerable heterogeneity with regards to g-catenin localization. As shown in Figure 1e (also summarized in Figure 1f , and further color images are available in Supplementary Figure S7) , g-catenin distribution ranged from exclusively cytosolic to strongly nuclear (in B10% of monocytes). The cells exhibiting intense nuclear g-catenin staining most likely represent the 'shoulder' of high expression observed in the flow cytometric data represented in Figure 1a . Such localization is suggestive of a novel nuclear function for g-catenin in monopoiesis, however, it should be noted that nuclear localization of catenins does not necessarily correlate with transcriptional activation of the Wnt signaling pathway. 12 As the above data suggested an important role for g-catenin in myeloid differentiation, we used an in vitro model of hematopoiesis to examine the effect of g-catenin knockdown (g-Cat KD). Retroviral transduction efficiencies (as assessed by green-fluorescent protein (GFP) positivity) were 27±10% for control short hairpin RNA (shRNA) and 17 ± 2% for g-Cat KD shRNA (n ¼ 4), and remained stable throughout in vitro culture. Figure 2a shows that GFP þ -sorted g-Cat KD cells exhibited an B80% reduction in g-catenin protein relative to sorted control cells, whereas corresponding b-catenin levels remained unaffected. These data support our previous observation that modulation of g-catenin level in normal HSPC fails to influence b-catenin level and localization. 4 We next examined the effect of g-catenin protein knockdown on the frequency of granulocytic, monocytic and erythroid progenitor cells using lineage discrimination markers (CD13 and CD36) to identify monocytic and erythroid lineages, and a granulocyte population (that also contains residual uncommitted cells; Figure 2b ). GFP þ -gated g-Cat KD cultures exhibited a sustained B30% decrease in monocyte progenitor cell frequency post transduction (Figure 2c ), which coincided with an increased frequency of erythroid progenitor cells (not shown). The frequency of granulocytic/uncommitted progenitors between cultures was unaffected. Morphological analysis confirmed the decreased frequency of monocytic cells in GFP þ -sorted g-Cat KD cultures, as shown in Figure 2d (further morphological images are shown in color in Supplementary Figure S8) .
To determine whether the development of lineage subsets was affected, cells were additionally labeled with a panel of differentiation markers: CD34, CD15, CD14, CD163, macrophage colony-stimulating factor receptor (M-CSFR; aka CD115) and GlyA. Surface marker expression between GFP þ control and g-Cat KD subpopulations was similar, except for the expression of M-CSFR on g-Cat KD monocytes, which was significantly reduced at both early and late stages of culture (Figures 2e and f) . g-Catenin shRNA had no significant effect on overall proliferation (Supplementary Figure S9) .
Expression of M-CSFR is regulated by PU.1, a transcriptional master regulator of myeloid differentiation that is required to sustain monocyte lineage commitment. 13 Reduced expression of M-CSFR on g-Cat KD monocytes (Figures 2e and f) suggested that g-catenin was required to maintain the expression of PU.1. Therefore, the lack of g-catenin would lead to a deficiency of PU.1, thereby explaining the decrease in monocyte frequency and M-CSFR expression in GFP þ g-Cat KD cultures. To establish whether this was the case, we modeled g-catenin protein silencing in the monocytic cell line, U937. As observed in Figure 2g , U937 exhibited very low endogenous levels of g-catenin, which were further decreased in the cytosol and nucleus of g-Cat KD. Nuclear PU.1 protein expression was 75% lower in g-Cat KD cells (PU.1 mRNA expression was also reduced, Supplementary Figure S10 ), which also displayed a 95% reduction in cytosolic M-CSFR expression. A similar effect on PU.1 protein and mRNA expression was obtained upon g-catenin silencing in another monocytic cell line, THP-1, although we were unable to detect M-CSFR expression in this line (also in Supplementary Figure S10) .
We are not the first to report that Wnt signaling can influence PU.1 expression. Constitutive b-catenin activation in murine HSCs resulted in PU.1 suppression, biasing commitment away from myeloid toward the megakaryocytic/erythroid lineage. 14 The fact that the upstream regulatory element of the PU.1 gene contains a consensus TCF-binding motif 15 suggests that b-catenin may directly repress PU.1. 16 In addition, the main TCF family member expressed in monocytic cells, TCF7L2, 17 contains distinct binding sites for both b-and g-catenin, which are able to differentially regulate TCF7L2-dependent transcription. 18 We, therefore, hypothesize that nuclear g-catenin is required in normal hematopoietic development to antagonize the suppressive influence of b-catenin over PU.1 expression, and that the high level of nuclear g-catenin seen in this lineage is required to sustain monocyte lineage commitment. We have been unable to confirm this directly, as we have not found it possible to promote the nuclear localization of either catenin in normal HSPC through their ectopic expression alone; 4 however, g-catenin has been reported to antagonize Wnt/b-catenin signaling in epithelial cells 19, 20 and there is precedent for increased nuclear localization of g-catenin, influencing cell fate in cardiac tissue. SETBP1 encodes SET-binding protein 1, a binding partner for the multi-function SET protein. This protein is encoded by the SET nuclear oncogene and is involved in apoptosis, transcription and nucleosome assembly. 1 The proposed functional outcome of this interaction is based on in vitro studies that demonstrate a protection of SET protein from protease cleavage that results in inhibition of protein phosphatase 2A activity, leading to higher rates of cell proliferation. 1 Initial identification of germline SETBP1 alterations affecting amino-acid residues between 858 and 871 have been described in patients with Schinzel-Giedion syndrome, associated with a congenital phenotype including mental retardation and facial deformities. 2 Recently, analysis of exome sequencing data from eight cases of atypical chronic myelogenous leukemia (aCML) led to the identification of recurrent somatic mutations involving SETBP1. Mutational frequency was 24% among 70 patients with aCML, and 4% among 82 patients with chronic myelomonocytic leukemia (CMML). The investigators were not able to detect similar mutations among 106 patients with acute myeloid leukemia (AML), 100 with myelodysplastic syndromes (MDS), 42 with chronic myeloid leukemia, 33 with primary myelofibrosis (PMF), 42 with polycythemia vera and 36 with essential thrombocythemia. 3 A more recent study identified SETBP1 mutations with an overall prevalence of 3.2% in a total of 658 cases 
